|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 8 (October 15), 1997:
pp. 3187-3194
Increased Phagocyte Fc RI Expression and Improved Fc-Receptor-Mediated Phagocytosis After In Vivo Recombinant Human Interferon- Treatment of Normal Human Subjects
By
Deborah E. Schiff,
Julie Rae,
Thomas R. Martin,
Bruce H. Davis, and
John T. Curnutte
From the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA; the Medical Research Service, Seattle Veterans Affairs Medical Center, Seattle, WA; and the Department of Clinical Pathology, William Beaumont Hospital, Royal Oak, MI.
 |
ABSTRACT |
Recombinant human interferon- (rhIFN-) decreases the frequency of serious infections in patients with chronic granulomatous disease (CGD) through an unknown mechanism. To test the hypothesis that it exerts a beneficial effect by enhancing clearance of microbes from the bloodstream and tissues, normal human subjects were treated in vivo with rhIFN-. Phagocyte opsonic receptor expression, serum opsonin levels, and phagocytosis of bacteria were then measured. A 4.7-fold increase in neutrophil expression of the high-affinity Fc-receptor (FcRI) was observed that peaked 48 hours after the initiation of rhIFN- treatment (P < .05). Monocyte expression of FcRI, FcRII, FcRIII, CD11a, CD11b, CD18, and HLA-DR also significantly increased with peak expression at 48 hours. Phagocytosis by neutrophils of killed Staphylococcus aureus opsonized with heat-inactivated pooled human serum significantly improved after rhIFN- treatment (P < .05) and correlated with FcRI expression by neutrophils (r = .8, P < .001). This increase in ingestion could be inhibited by anti-FcRI monoclonal antibodies. Levels of the serum opsonin lipopolysaccharide-binding protein also significantly increased after in vivo rhIFN- (P < .05). These results suggest that the protective effect of rhIFN- in patients with CGD may involve improved microbial clearance. Moreover, improved phagocyte trafficking may occur secondary to increased expression of monocyte  2 -integrins. Because these IFN--related improvements in host defense were seen in normal hosts, rhIFN- may have broader applications in the treatment of various disorders of immunity in addition to its demonstrated efficacy in CGD.
| |
INTRODUCTION |
RECOMBINANT HUMAN interferon- (rhIFN-), a lymphokine that exerts pleiotropic effects on the immune system, has been shown to reduce the incidence of severe infections in patients with chronic granulomatous disease (CGD), although the mechanism by which it exerts a beneficial clinical effect in these patients is not known.1-3 The multicenter phase III study of rhIFN- therapy in patients with CGD failed to show an improvement in neutrophil oxidative metabolism as determined by nitroblue tetrazolium reduction, neutrophil superoxide formation, and in vitro Staphylococcus aureus killing.1 Subsequent studies further showed no change in the levels of cytochrome b558 and no change in the activities of cytosol and membrane NADPH oxidase components using a cell free activation system.2,3 These findings were congruous with the fact that all the major genetic forms of CGD were equally responsive to rhIFN-. In addition, specific mutations found to be responsible for cases of CGD in recent years (including deletions, missense mutations, and stop codons that lead to structural defects in NADPH oxidase) predictably would not be amenable to correction with rhIFN- therapy.4-7 One hypothesis to explain its beneficial effect in patients with CGD is that it improves clearance of microbes from the bloodstream and tissues.
This postulated augmentation of microbial clearance by rhIFN- could be mediated, at least in part, by its ability to induce increased expression of FcRI (or CD64, the high-affinity Fc receptor for IgG) in phagocytes. This effect has been demonstrated both in vitro using cultured neutrophils, monocytes, and myeloid cells8-13 and in vivo in patients with CGD, cancer, and arthritis.14-17 However, the study of the immunomodulatory effects of IFN- in these patients is complicated by polypharmacy and intercurrent illnesses. To eliminate these confounding variables, the effects of in vivo rhIFN- in normal human subjects were examined in this study. The expression of opsonic receptors on phagocytes was measured, as were levels of serum opsonins, and correlated with the extent of ingestion of bacteria by neutrophils after the treatment of normal human subjects with rhIFN-. It was found that in vivo treatment of normal human subjects with rhIFN- led to increased expression of FcRI by their phagocytes and a related improvement in FcR-mediated phagocytosis by neutrophils. In addition, rhIFN- treatment was associated with increased expression on monocytes of the opsonic receptors FcRII, FcRIII, and CR3 (CD11b/CD18) as well as increased serum levels of the opsonin lipopolysaccharide-binding protein (LBP).
| |
MATERIALS AND METHODS |
Study design.
Volunteers were recruited from the normal donor pool of the General Clinical Research Center of Scripps Clinic and Research Foundation (La Jolla, CA). Eight women and eight men, aged 26 to 42 years, participated in the study. Medical history, physical examination, and routine laboratory investigations were normal in all subjects. The subjects did not use medication, were nonsmokers, and had no febrile illnesses 1 month before the study. Informed consent was obtained according to the rules of the Scripps Clinic and Research Foundation Human Subjects Committee. rhIFN- (Genentech, South San Francisco, CA) was administered at a dose of 0.05 mg/m2/dose subcutaneously (SC) daily for 2 days (the dose used in the phase III study of IFN- in patients with CGD was 0.05 mg/m2 SC administered three times weekly).1 Prophylactic acetaminophen (650 to 1,000 mg orally) was administered before rhIFN- and then every 4 hours as needed to minimize the incidence of fever and myalgia secondary to rhIFN-. Subjects were under medical observation during the first 48 hours of the trial. No significant toxicity was observed. Mild adverse reactions were limited to headache (4 subjects), myalgias (2 subjects), and nausea (1 subject).
Monoclonal antibodies (MoAbs) and antibody fragments.
The following MoAbs and antibody fragments were used in direct immunofluorescent staining and phagocytosis inhibition studies. F(ab')2 to FcRI (32.2) and MoAbs to FcRI (22, IgG1; 197, IgG2a), FcRII (IV.3, IgG2b), and FcRIII (3G8, IgG1) were purchased from Medarex (Annandale, NJ). MoAb to CD14 (MEM-15, IgG1), CD11a (MEM-25, IgG1), CD11b (CR3, IgG1), CD18 (MEM-48, IgG1), and HLA-DR (HL38, IgG1) and isotypic control MoAbs were obtained from Caltag (South San Francisco, CA). Control murine F(ab')2 fragments were purchased from Cappel (Durham, NC). All of the antibodies listed above were obtained in their fluorescein isothiocyanate (FITC)-conjugated form except the antibodies used in the phagocytosis inhibition studies (197, 32.2, and their respective isotype controls).
Quantitative measurement of phagocyte opsonic receptor expression.
A previously described method was used for measuring the binding of FITC-labeled MoAbs and isotype control murine MoAbs to leukocytes prepared from erythrocyte-lysed whole blood.14,18,19 Briefly, 100 µL of EDTA-anticoagulated whole blood diluted with phosphate-buffered saline (PBS) to a concentration of 2.5 × 106 leukocytes/mL were incubated with 5 µL of saturating amounts of MoAb. Erythrocytes were lysed, and then leukocytes were stabilized and fixed using the Coulter Q-Prep lysis procedure (Coulter Electronics, Hialeah, FL). This method allowed rapid analysis of small aliquots of whole blood with minimal sample manipulation.18,19 All samples were washed with PBS and then resuspended in 300 µL of PBS. Flow cytometric analysis was performed on 10,000 leukocytes per sample using a FACScan with Cell Quest software (Becton Dickinson Immunocytometry Systems, San Jose, CA). Neutrophils and monocytes were identified by forward and right angle light scattering properties. In pilot experiments using double staining with anti-CD14/CD45 MoAbs, this gating technique identified neutrophil and monocyte populations that were greater than 97% and greater than 90% pure, respectively. Expression of surface markers was quantitated using Quantum FITC-standardized beads and accompanying software (Flow Cytometry Standards Corp, San Juan, Puerto Rico). Results were reported as FITC mean equivalent soluble fluorescence (MESF ) units. Quantitation of surface marker expression in FITC MESF units included the correction of MESF values for nonspecific binding, as detected by isotypic control antibody.
Leukocyte purification for phagocytosis assay.
Leukocytes were purified by a whole-blood lysis method.20 Whole blood (10 mL) was collected into Vacutainer tubes containing sodium heparin (Becton Dickinson, Rutherford, NJ). To each milliliter of blood was added 14 mL of room temperature NH4Cl lysing solution (168 mmol/L NH4Cl, 10 mmol/L KHCO3 , and 0.1 mmol/L tetrasodium EDTA, pH 7.4). The mixture was allowed to stand for 3 to 5 minutes at room temperature, after which the samples were centrifuged at 300g for 5 minutes. Residual erythrocytes were lysed for 3 more minutes. The remaining leukocytes were washed twice in PBS at 4°C and resuspended in assay buffer (PBS containing 0.1% gelatin, 5 mmol/L glucose, and 0.5 mmol/L MgCl2 ) at a concentration of 1 × 107 leukocytes/mL. Viability of cells as determined by trypan blue exclusion was greater than 92%.
Phagocytosis of S aureus by neutrophils.
S aureus-BODIPY BioParticles (Molecular Probes, Eugene, OR) were opsonized with pooled human serum (PHS) or PHS that had been heated to 56°C for 30 minutes to inactivate complement (HI-PHS). The following procedure was followed to estimate FcR-mediated phagocytosis by neutrophils. At time 0, HI-PHS-opsonized BioParticles (2 × 107 in 200 µL of assay buffer) were added to leukocytes (1 × 106 in 100 µL of assay buffer). Samples were brought to a final volume of 400 µL and incubated in the dark at 37°C. At 0 and 120 minutes, 50-µL aliquots were removed and added to 400 µL of trypan blue 0.1% in PBS to quench external fluorescence.21-24 Linear mean fluorescence intensity (MFI) of the gated neutrophil population was determined by flow cytometry. Phagocytosis was calculated as MFI (subject)/MFI (control) × 100. The normal control was the same person for the entire course of the regimen for each given subject. A similar procedure was followed to determine complement-mediated phagocytosis by neutrophils, except that half the number of BioParticles was used and the incubation time was 30 minutes instead of 120 minutes. For the inhibition studies, leukocytes were preincubated with 20 µg/mL of the following MoAb or F(ab')2 fragments for 1 hours at 4°C: murine IgG2a, anti-FcRI MoAb (197), murine nonspecific F(ab')2 , and anti-FcRI F(ab')2 (32.2). At time 0, BioParticles (2 × 107 in 200 µL of assay buffer) were added to leukocytes (1 × 106) with or without antibody or antibody fragments in assay buffer. The assay was then performed as described above.
Measurement of serum opsonins and acute-phase reactants. Complement, Ig, and C-reactive protein (CRP) levels were measured in the Scripps Clinic clinical laboratory. Soluble CD14 (sCD14) and LBP levels were determined by enzyme-linked immunosorbent assay (ELISA) as previously described using MoAb pairs raised against recombinant human LBP and sCD14.25 Serum levels of neopterin and 2 -microglobulin (2 -m) were assessed using commercially available radioimmunoassay kits from ICN Biomedicals (Costa Mesa, CA) and T Cell Diagnostics (Cambridge, MA), respectively. The neopterin standard curve was linear from 1.56 to 100 ng/mL; the 2 -m standard curve was linear from 20 to 400 ng/mL. Soluble intercellular adhesion molecule (sICAM) was assessed using a commercially available ELISA kit (Endogen, Boston, MA).
Measurement of peripheral blood leukocyte counts and differentials.
Peripheral blood leukocyte counts were determined in the Scripps Clinic hematology laboratory by an automated STKS Analyzer (Coulter, Miami, FL). A manual differential was performed in addition to the automated complete blood count.
Statistical analysis.
Groups before and 24 hours, 48 hours, 72 hours, and 7 days after rhIFN- administration were compared by repeated measures ANOVA and P < .05 was considered significant. Group data are expressed as the mean ± standard error (SE), unless otherwise stated.
| |
RESULTS |
Leukocyte and absolute neutrophil counts after in vivo rhIFN- treatment.
Peripheral leukocyte counts and neutrophil counts decreased significantly after in vivo rhIFN-. Leukocyte and neutrophil counts reached their nadir 48 hours after the administration of the first dose of rhIFN-, with troughs of 4.02 ± 0.96 × 109/L and 2.24 ± 1.06 × 109/L, respectively. Both returned to near pretreatment values by day 7 (Fig 1).
View larger version (18K):
[in this window]
[in a new window]
| Fig 1.
Effect of rhIFN- on peripheral blood leukocyte counts. Mean ± SE leukocyte ( ) and neutrophil ( ) counts after in vivo rhIFN- (0.05 mg/m2 SC daily for 2 doses) administered to 16 healthy volunteers are shown. Asterisks indicate statistical significance (P < .05).
|
|
Expression of opsonic receptors by phagocytes after in vivo rhIFN- administration.
In vivo rhIFN- treatment was associated with a significant increase in FcRI expression on neutrophils (Fig 2), although expression of FcRII, FcRIII, CR3 (CD11b/CD18), and CD14 did not vary significantly from baseline at any time point (data not shown). FcRI expression on neutrophils significantly increased from baseline by 24 hours after initiating in vivo rhIFN- treatment (P < .05). Peak expression of FcRI by neutrophils was seen at 48 hours, with a mean 4.7-fold increase in expression. Before rhIFN- treatment, 36% of neutrophils from study subjects were positive for FcRI expression when compared with an isotypic control (SD = 24; n = 12), whereas 95% were positive at 48 hours (SD = 4; n = 12). A substantial decrease in FcRI expression was seen within 48 hours of the last rhIFN- dose. By day 7 of the treatment regimen, FcRI expression by neutrophils returned to pretreatment levels.
View larger version (20K):
[in this window]
[in a new window]
| Fig 2.
Effect of in vivo rhIFN- administration on FcRI expression on circulating neutrophils. FcRI expression was measured by flow cytometry as described in the Materials and Methods. Expression is depicted as FITC MESF ± SE for 12 healthy volunteers () and 6 untreated controls (). Asterisks indicate statistical significance (P < .05)
|
|
Consistent with its known role as an activator of monocytes, in vivo rhIFN- treatment was associated with a significant increase in the expression on monocytes of Fc receptors FcRI, FcRII, and FcRIII; leukocyte integrin subunits CD11a, CD11b, and CD18; and HLA class II antigen HLA-DR (Fig 3). At 48 hours, monocytes exhibited maximal 3.3-, 1.2-, 2.1-, 3.1-, 1.6-, 2.0-, and 1.9-fold increases from baseline expression of FcRI, FcRII, FcRIII, HLA-DR, CD11a, CD11b, and CD18, respectively (all P values < 0.05); monocyte expression of CD14 did not vary significantly from baseline after rhIFN- administration (Fig 3).
View larger version (27K):
[in this window]
[in a new window]
| Fig 3.
The effect of in vivo rhIFN- administration on monocyte surface molecule expression. In vivo rhIFN- was associated with a significant increase in expression of FcRI (A), FcRII (B), FcRIII (C), HLA-DR (D), CD11a (F ), CD11b (G), and CD18 (H). Monocyte expression of CD14 (E) failed to change significantly. Results are reported as FITC MESF ± SE from patients (; n = 12) who received rhIFN- per protocol and untreated normal controls (; n = 6). Asterisks indicate statistical significance (P < .05).
|
|
The effect of in vivo rhIFN- administration on phagocytosis of S aureus by neutrophils.
In vivo rhIFN- treatment was associated with a significant improvement in the ability of neutrophils to ingest S aureus-BODIPY BioParticles when opsonized with complement-depleted HI-PHS, but not with pooled human serum (Fig 4). Neutrophils obtained from normal subjects 48 hours after initiating in vivo rhIFN- treatment displayed a 91% increase in their capacity to ingest HI-PHS-opsonized killed S aureus compared with baseline. Because the kinetics and magnitude of complement-mediated phagocytosis of S aureus by human neutrophils in this system are faster and greater than those seen with FcR-mediated phagocytosis, it is possible that the presence of complement in the experiment depicted in Fig 4B masked the increase in FcR-mediated phagocytosis. This increase in FcR-mediated phagocytosis (Fig 4A) significantly correlated with FcRI expression by neutrophils (Fig 5; r = .8, P < .001).
View larger version (15K):
[in this window]
[in a new window]
| Fig 4.
The effect of in vivo rhIFN- on bacterial ingestion by neutrophils. These graphs show the mean ± SE phagocytosis by neutrophils of S aureus-BODIPY BioParticles opsonized with complement-depleted serum (A; ; n = 6) or pooled human serum with intact complement (B; ; n = 4). Phagocytosis by neutrophils from rhIFN--treated subjects was calculated as MFI (subject)/MFI (control) × 100. Asterisks indicate statistical significance (P < .05).
|
|
View larger version (20K):
[in this window]
[in a new window]
| Fig 5.
Correlation of FcRI expression by neutrophils with phagocytosis by neutrophils of S aureus opsonized with complement-depleted pooled human serum. FcRI expression by neutrophils from study subjects was determined by direct immunostaining before and after in vivo rhIFN- administration (0.05 mg/m2 SC daily for 2 days). Correlation of FcRI expression by neutrophils with their ability to perform phagocytosis of HI-PHS-opsonized S aureus BioParticles was determined by regression analysis. FcRI expression by neutrophils correlated directly with ability to ingest HI-PHS-opsonized S aureus (r = .8, P < .05).
|
|
Two antibodies that specifically bind to human FcRI, MoAb 197 and F(ab')2 32.2, inhibited phagocytosis of HI-PHS-opsonized S aureus by neutrophils by 55% and 31%, respectively, when neutrophils were obtained from subjects 48 hours after the initiation of rhIFN- treatment (Fig 6). Moreover, nonspecific murine IgG2a that binds preferentially to Fc receptor FcRI blocked the ingestion of S aureus by 62% (Fig 6). None of these antibody preparations was significantly inhibitory when added to neutrophils obtained from subjects before rhIFN- treatment (Fig 6).
View larger version (22K):
[in this window]
[in a new window]
| Fig 6.
The effects of FcRI antagonists on rhIFN--enhanced bacterial ingestion by neutrophils. The graph shows the effect of anti-FcRI MoAb (197) and F(ab')2 (32.2), and control murine IgG2a (mIgG2a) and murine F(ab')2 [mF(ab')2 ] on phagocytosis of HI-PHS-opsonized S aureus-BODIPY BioParticles by neutrophils. The mean MFI of neutrophils obtained from two different study subjects ( ) before in vivo rhIFN- administration (0.05 mg/m2/dose SC daily for 2 days) and ( ) 48 hours after the initiation of in vivo rhIFN- treatment are depicted. Asterisks indicate statistically significant inhibition by the MoAb or F(ab')2 when compared with the corresponding 48-hour control in which no MoAb or F(ab')2 was present (Student's t-test, P < .05).
|
|
Serum opsonin and acute phase reactant levels after in vivo rhIFN-.
The serum levels of neopterin (an intermediate product of the biosynthesis of tetrahydrobiopterin)26-29 and 2 -m (a short polypeptide chain located extracellularly in the class I major human histocompatibility complex)29 have been used to monitor in vivo responses to therapeutic IFN-.28-30 In the normal subjects treated with rhIFN- in this study, both neopterin and 2 -m levels peaked at 48 hours after the first dose of rhIFN-, with a 3.1-fold increase over pretreatment seen for neopterin and a 1.7-fold increase for 2 -m (Table 1). Similarly, the serum level of an opsonic protein LBP peaked at 24 hours, with a 39% increase over baseline (Table 1). LBP is a glycoprotein that binds to lipopolysaccharide (LPS) with high affinity and enhances LPS effects on CD14+ cells.31 None of the other serum opsonins or acute-phase reactants measured (ie, serum IgG, IgM, complement C3, CRP, sICAM, and sCD14) increased significantly after in vivo rhIFN- (Table 1).
| |
DISCUSSION |
Administration of rhIFN- has been established by an international, double-blinded, placebo-controlled study as an effective prophylactic treatment regimen in patients with CGD for reducing the number of serious bacterial and fungal infections.1 Unexpectedly, in that study, administration of rhIFN- failed to correlate with enhanced neutrophil or monocyte superoxide production or in vitro S aureus bacterial killing.2,3 Because no laboratory test correlated with administration of rhIFN-, it has been suggested that expression of FcRI be used as a measure of in vivo biologic activity of IFN-.14,16 Increased FcRI expression secondary to IFN- has previously been shown in vivo in patients with cancer, arthritis, and CGD.14-17 However, patients with underlying infections or inflammatory conditions may not be the ideal models for studying FcRI expression, because it is known that inflammation and infection upregulate FcRI.14,32,33 In this present study, in vivo rhIFN- treatment of normal human subjects (in the absence of inflammation and infection) induced increased FcRI expression by neutrophils and monocytes.
This study extends previous IFN- studies by showing a functional correlate to enhanced expression of FcRI: improved FcR-mediated phagocytosis by neutrophils. In vivo rhIFN- treatment was associated with a significant improvement in the ability of neutrophils to ingest killed S aureus when opsonized with complement-depleted pooled human serum (HI-PHS). The importance of Fc-receptor function in host defense has previously been shown by reports that impaired phagocyte Fc-receptor function in patients with alcoholic cirrhosis and end-stage renal disease is associated with an increased incidence of pyogenic infections in these patients.34,35
It is known that infection is associated with the release of various cytokines and inflammatory mediators. For example, streptococcal antigens are potent inducers of IFN- production.36,37 Not surprisingly, phagocytes isolated from patients with group A -hemolytic streptococcal pharyngitis have increased expression of FcRI.33 Simms et al32 showed that patients with acute bacterial infection had an increased capacity to perform FcR-mediated phagocytosis. This effect was correlated with FcRI upregulation. Presumably, this upregulation in phagocytic function represents a physiologic response to infection. As shown in this study, in vivo rhIFN- treatment mimics this physiologic response to infection.
Capsoni et al38 looked at the effect of in vitro IFN- treatment on human neutrophil FcR-mediated phagocytosis and found that doses up to 500 U/mL (1.7 ng/mL) had no effect in their experimental model. This in vitro dose was comparable to plasma levels observed in cancer patients treated with IFN-.39 It is possible that their results conflict with the results of this study due to the short duration of IFN- treatment (30 minutes at 37°C) used in their model.38 In this study, FcRI expression by neutrophils was upregulated by 24 hours (Fig 2) but not 4 hours after the initiation of therapy (data not shown).
The washout kinetics of IFN--related effects seen in this study were also informative. Neutrophil and monocyte expression of FcRI (as well as monocyte expression of FcRII, FcRIII, CD11a, CD11b, and CD18) all substantially decreased within 48 hours of cessation of rhIFN- and were back to normal baseline levels by day 7. Furthermore, other markers of IFN- treatment (serum neopterin, 2 -m, and LBP) also returned to baseline by day 7. The kinetics of these IFN- effects are similar to the in vitro effects of IFN- on monocyte and monocyte-like cell line U937 expression of FcRI and FcRII mRNA and protein as reported by Comber et al.12,13 These kinetics of rhIFN--related effects have potentially important implications concerning the dosing frequency of rhIFN- prophylaxis in CGD.
IFN- has been shown to be a potent immunomodulator, with in vitro effects on the monocyte/macrophage defense system.17,40-43 In this study, the effect of in vivo rhIFN- on the kinetics and magnitude of monocyte surface molecule expression were examined. As others have previously reported, increased expression of 2 -integrins and HLA-DR by monocytes after rhIFN- treatment was observed.30,44-46 Contrary to other reports, no significant change in expression of the LPS/LBP receptor CD14 was seen.9,47 In addition to the expected increase in FcRI, an unexpected increase in FcRIII expression by monocytes was seen. Monocyte FcRII expression also significantly increased, although, as others have reported,12,13 the magnitude of this increase (1.2-fold) was much less striking than that seen with FcRI (3.3-fold).
As an immunomodulatory cytokine, IFN- plays a role in the induction of serum factors and acute-phase proteins. Two such proteins, neopterin and 2 -m, are known to be induced by IFN- treatment.28-30 As expected, in vivo rhIFN- treatment did induce a significant increase in serum neopterin and 2 -m levels in normal subjects. Conflicting reports exist in the literature regarding IFN- and complement synthesis.48,49 In this study, in vivo IFN- therapy had no significant effect on either C3 or C4 levels. Contrary to earlier reports, sCD14 did not significantly increase after in vivo IFN- treatment.30 However, these results were consistent with the failure to find a significant change in membrane CD14 expression by monocytes and neutrophils after in vivo IFN-. In vivo rhIFN- treatment was associated with a significant increase in serum LBP levels noted 24 hours after the initiation of treatment. LBP is known to be an acute-phase reactant produced predominantly in the liver.50-53 This is the first report that IFN- induces LBP as part of an acute-phase response.
In this study, rhIFN- treatment was well tolerated at a dose of 0.05 mg/m2 SC daily for 2 doses. Many of the study subjects received acetaminophen to minimize the expected fever, headache, and myalgia. An acetaminophen-related effect on the parameters studied cannot be excluded. However, an in vitro study using therapeutic concentrations of acetaminophen showed inhibition of phagocytosis rather than the improvement in phagocytosis seen in this study.54 Laboratory results were remarkable for a significant decrease in total leukocyte and neutrophil counts after rhIFN- treatment. This effect was not reported in the multicenter, phase III study of IFN- in patients with CGD in which longer interval time points were evaluated,1 although it was seen in studies in which IFN- was administered over a short term, as in this study.46 Landmann et al30 reported tachyphylaxis of this and other IFN--related effects in their study of prolonged SC IFN- administration. The rapid onset of decreased leukocyte and neutrophil counts in our study makes it unlikely that this effect is secondary to decreased leukocyte production in the bone marrow.
In conclusion, the protective effect of rhIFN- in patients with CGD may be related to upregulation of Fc-receptor expression by phagocytes, increased serum levels of opsonin LBP, and a subsequent improvement in the ability of phagocytes to ingest microbes. In addition, improved phagocyte trafficking may occur secondary to increased expression of monocyte 2 -integrins. Because these improvements in host defense were seen in normal hosts, rhIFN- may have broader applications as adjuvant treatment in disorders of host defense including but not limited to CGD.
| |
FOOTNOTES |
Submitted November 20, 1996;
accepted June 5, 1997.
Supported by National Institutes of Health Grants No. AI-24838 (J.T.C.), GM-37696 (T.R.M.), and RR-00833 (Scripps Clinic GCRC); Public Health Services Grant No. DK07022 (D.E.S.); the Medical Research Service of the Department of Veterans Affairs (T.R.M.); and Genentech, Inc.
Address reprint requests to Deborah E. Schiff, MD, Department of Molecular and Experimental Medicine, CAL-1, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
The authors thank Valerie Moreau for assistance with preparation of the manuscript, the nurses and laboratory personnel of the Scripps Clinic GCRC for invaluable help, John Ruzinski from the Seattle VA for running the serum sCD14 and LBP assays, and Brian Paasch and the department of Assay Services at Genentech for running the neopterin, 2 -m, and sICAM assays.
| |
REFERENCES |
1.
The International Chronic Granulomatous Disease Cooperative Study Group:
A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease.
N Engl J Med
324:509,
1991[Abstract]
2.
Muhlebach TJ,
Gabay J,
Nathan CF,
Erny C,
Dopfer G,
Schroten H,
Wahn V,
Seger RA:
Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins.
Clin Exp Immunol
88:203,
1992[Medline]
[Order article via Infotrieve]
3.
Woodman RC,
Erickson RW,
Rae J,
Jaffe HS,
Curnutte JT:
Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: Evidence against enhanced neutrophil oxidase activity.
Blood
79:1558,
1992[Abstract/Free Full Text]
4.
Roos D,
de Boer M,
Kuribayashi F,
Meischl C,
Weening RS,
Segal AW,
Ahlin A,
Nemet K,
Hossle JP,
Bernatowska-Matuszkiewicz E,
Middleton-Price H:
Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease.
Blood
87:1663,
1996[Free Full Text]
5.
Cross AR,
Curnutte JT,
Rae J,
Heyworth PG:
Hematologically important mutations: X-linked chronic granulomtous disease.
Blood Cells Mol Dis
22:90,
1996[Medline]
[Order article via Infotrieve]
6. Curnutte JT: Chronic granulomatous disease: The solving of a clinical riddle at the molecular level. Clin Immunol Immunopathol 67:S2, 1993
7.
Hopkins PJ,
Bemiller LS,
Curnutte JT:
Chronic granulomatous disease: Diagnosis and classification at the molecular level.
Clin Lab Med
12:277,
1992[Medline]
[Order article via Infotrieve]
8.
Petroni KC,
Shen L,
Guyre PM:
Modulation of human polymorphonuclear leukocyte IgG Fc receptor-mediated functions by IFN-gamma and glucocorticoids.
J Immunol
140:3467,
1988[Abstract]
9.
Jayaram Y,
Buckle AM,
Hogg N:
The Fc receptor, FcRI, and other activation molecules on human mononuclear phagocytes after treatment with interferon-gamma.
Clin Exp Immunol
75:414,
1989[Medline]
[Order article via Infotrieve]
10.
Guyre PM,
Morganelli PM,
Miller R:
Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes.
J Clin Invest
72:393,
1983
11.
Akerly WL 3rd,
Guyre PM,
Davis BH:
Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties.
Blood
77:607,
1991[Abstract/Free Full Text]
12.
Comber PG,
Rossman MD,
Rappaport ER,
Chien P,
Hogarth PM,
Schreiber AD:
Modulation of human mononuclear phagocyte Fc-gamma-RII mRNA and protein.
Cell Immunol
124:292,
1989[Medline]
[Order article via Infotrieve]
13.
Comber PG,
Lentz V,
Schreiber AD:
Modulation of the transcriptional rate of Fc-gamma receptor mRNA in human mononuclear phagocytes.
Cell Immunol
145:324,
1992[Medline]
[Order article via Infotrieve]
14.
Davis BH,
Bigelow NC,
Curnutte JT,
Ornvold K:
Neutrophil CD64 expression: Potential diagnostic indicator of acute inflammation and therapeutic monitor of interferon-gamma therapy.
Lab Hematol
1:3,
1995
15.
Goulding NJ,
Knight SM,
Godolphin JL,
Guyre PM:
Increase in neutrophil Fc-gamma receptor I expression following interferon gamma treatment in rheumatoid arthritis.
Ann Rheum Dis
51:465,
1992[Abstract/Free Full Text]
16.
Huizinga TWJ,
van der Schoot CE,
Roos D,
Weening RS:
Induction of neutrophil Fc-gamma receptor I expression can be used as a marker for biologic activity of recombinant interferon-gamma in vivo [letter].
Blood
77:2088,
1991[Free Full Text]
17.
Maluish AE,
Urba WJ,
Longo DL,
Overton WR,
Coggin D,
Crisp ER,
Williams R,
Sherwin SA,
Gordon K,
Steis RG:
The determination of an immunologically active dose of interferon gamma in patients with melanoma.
J Clin Oncol
6:434,
1988[Abstract]
18.
Caldwell CW,
Taylor HM:
A rapid, no-wash technique for immunophenotypic analysis by flow cytometry.
Am J Clin Pathol
86:600,
1986[Medline]
[Order article via Infotrieve]
19.
Kotylo PK,
Baenzinger JC,
Yoder MC,
Engle WA,
Bolinger CD:
Rapid analysis of lymphocyte subsets in cord blood.
Am J Clin Pathol
93:263,
1990[Medline]
[Order article via Infotrieve]
20. Direct immunofluorescence staining of cell surface antigens in unseparated blood, in Becton Dickinson Monoclonal Antibody Source Book. Mountain View, CA, Becton Dickinson, 1988, section 2.11
21.
Wan CP,
Park CS,
Lau BHS:
A rapid and simple microfluorometric phagocytosis assay.
J Immunol Methods
162:1,
1993[Medline]
[Order article via Infotrieve]
22.
Bjerknes R,
Bassoe C-F:
Phagocyte C3-mediated attachment and internalization: Flow cytometric studies using a fluorescence quenching technique.
Blut
49:315,
1984[Medline]
[Order article via Infotrieve]
23.
Martin RJ,
Kusel JR,
Robertson SJ,
Minta A,
Haugland RP:
Distribution of a fluorescent ivermectin probe, bodipy ivermectin, in tissues of the nematode parasite Ascaris suum.
Parasitol Res
78:341,
1992[Medline]
[Order article via Infotrieve]
24.
Martin RJ,
Kusel JR:
On the distribution of a fluorescent ivermectin probe (4',5,7 dimethyl-bodipy proprionylivermectin) in Ascaris membranes.
Parasitology
104:549,
1992
25. Dubin W, Martin TR, Swoveland P, Leturcq DJ, Moriarty AM, Tobias PS, Bleecker ER, Goldblum SE, Hasday JD: Asthma and endotoxin: Lipopolysaccharide-binding protein and soluble CD14 in bronchoalveolar compartment. Am J Physiol 270:L736, 1996
26.
Hobarth K,
Szabo N,
Hallas A,
Aulitzky W,
Marberger M:
Serum neopterin as a parameter for monitoring the course of renal cell carcinoma during interferon-gamma therapy.
Clin Immunol Immunopathol
70:241,
1994[Medline]
[Order article via Infotrieve]
27.
Moutabarrik A,
Takahara S,
Namiki M,
Kameoka H,
Seguchi T,
Yokokawa K,
Takano Y,
Sonoda T,
Ishibashi M,
Zsaid D,
Okuyama A:
Contrasting effects of interferon-gamma and interleukin-4 on neopterin generation from human adherent monocytes.
Lymphokine Cytokine Res
11:327,
1992[Medline]
[Order article via Infotrieve]
28.
Werner-Felmayer G,
Werner ER,
Fuchs D,
Hausen A,
Reibnegger G,
Wachter H:
Neopterin formation and tryptophan degradation by human myelomonocytic cell line (THP-1) upon cytokine treatment.
Cancer Res
50:2863,
1990[Abstract/Free Full Text]
29.
Hofmann B,
Bass H,
Nishanian P,
Faisal M,
Figlin RA,
Sarna GP,
Fahey JL:
Different lymphoid cell populations produce varied levels of neopterin, 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
Clin Exp Immunol
88:548,
1992[Medline]
[Order article via Infotrieve]
30.
Landmann R,
Ludwig C,
Wesp M,
Fischer A,
Obrist R,
Knusli C,
Denz H,
Obrecht JP:
Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: Differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
J Interferon Res
12:103,
1992[Medline]
[Order article via Infotrieve]
31.
Schumann RR,
Leong SR,
Flaggs CW,
Gray PW,
Wright S,
Mathison JC,
Tobias PS,
Ulevitch RJ:
Structure and function of lipopolysaccharide binding protein.
Science
249:1429,
1990[Abstract/Free Full Text]
32.
Simms HH,
Frank MM,
Quinn TC,
Holland S,
Gaither TA:
Studies of phagocytosis in patients with acute bacterial infections.
J Clin Invest
83:252,
1989
33.
Guyre PM,
Campbell AS,
Kniffin WD,
Fanger MW:
Monocytes and polymorphonuclear neutrophils of patients with streptococcal pharyngitis express increased numbers of type I IgG Fc receptors.
J Clin Invest
86:1892,
1990
34.
Gomez F,
Ruiz P,
Schreiber AD:
Impaired function of macrophage Fc-gamma receptors and bacterial infection in alcoholic cirrhosis.
N Engl J Med
331:1122,
1994[Abstract/Free Full Text]
35.
Ruiz P,
Gomez F,
Schreiber AD:
Impaired function of macrophage Fc-gamma receptors in end-stage renal disease.
N Engl J Med
322:717,
1990[Abstract]
36.
Matsubara S,
Suzuki F,
Ishida N:
Induction of immune interferon in mice treated with a bacterial immunopotentiator, OK 432.
Cancer Immunol Immunother
6:41,
1979
37.
Kimura S,
Inoue T,
Yamashita T,
Midorikawa Y,
Arai S,
Sendo F:
Production of factor(s) that render polymorphonuclear leukocytes cytotoxic from spleen cells stimulated with streptococcal preparation, OK-432.
Cancer Res
47:6204,
1987[Abstract/Free Full Text]
38.
Capsoni F,
Bonara P,
Minonzio F,
Ongari AM,
Colombo G,
Rizzardi GP,
Zanussi C:
The effect of cytokines on human Fc receptor-mediated phagocytosis.
J Clin Lab Immunol
34:115,
1991[Medline]
[Order article via Infotrieve]
39.
Digel W,
Zahn G,
Heinzel G,
Porzsolt F:
Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon-gamma in cancer patients.
Cancer Immunol Immunother
34:169,
1991[Medline]
[Order article via Infotrieve]
40.
Basham TY,
Merigan TC:
Recombinant interferon-gamma increases HLA-DR synthesis and expression.
J Immunol
130:1492,
1993[Abstract]
41.
Skerrett SJ,
Martin TR:
Recombinant murine interferon-gamma reversibly activates rat alveolar macrophages to kill Legionella pneumophila.
J Infect Dis
166:1354,
1992[Medline]
[Order article via Infotrieve]
42.
Skerrett SJ,
Martin TR:
Intratracheal interferon-gamma augments pulmonary defenses in experimental legionellosis.
Am J Respir Crit Care Med
149:50,
1994[Abstract]
43.
Kleinerman ES,
Kurzrock R,
Wyatt D,
Quesada JR,
Gutterman JU,
Fidler IJ:
Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon.
Cancer Res
46:5401,
1986[Abstract/Free Full Text]
44.
Vey E,
Zhang J,
Dayer J:
IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells.
J Immunol
149:2040,
1992[Abstract]
45.
Wang J,
Beekhuizen H,
Van Furth R:
Surface molecules involved in the adherence of recombinant interferon-gamma (rIFN-gamma)-stimulated human monocytes to vascular endothelial cells.
Clin Exp Immunol
95:263,
1994[Medline]
[Order article via Infotrieve]
46.
Reinisch W,
Tillinger W,
Lichtenberger C,
Gangl A,
Willheim M,
Scheiner O,
Steger G:
In vivo induction of HLA-DR on human neutrophils in patients treated with interferon-gamma [letter].
Blood
87:3068,
1996[Free Full Text]
47.
Landmann R,
Ludwig C,
Obrist R,
Obrecht JP:
Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages.
J Cell Biochem
47:317,
1991[Medline]
[Order article via Infotrieve]
48.
Tsukamoto H,
Nagasawa K,
Ueda Y,
Mayumi T,
Furugo I,
Tsuru T,
Niho Y:
Effects of cell differentiation on the synthesis of the third and fourth component of complement (C3, C4) by the human monocytic cell line U937.
Immunology
77:621,
1992[Medline]
[Order article via Infotrieve]
49.
Lappin DF,
Birnie GD,
Whaley K:
Modulation by interferons of the expression of monocyte complement genes.
Biochem J
268:387,
1990[Medline]
[Order article via Infotrieve]
50.
Grube BJ,
Cochrane CG,
Ye RD,
Green CE,
McPhail LC,
Ulevitch RJ,
Tobias PS:
Lipopolysaccharide binding protein expression in primary human hepatocytes and HepG2 hepatoma cells.
J Biol Chem
269:8477,
1994[Abstract/Free Full Text]
51.
Ramadori G,
Meyer zum Buschenfelde KH,
Tobias PS,
Mathison JC,
Ulevitch RJ:
Biosynthesis of lipopolysaccharide-binding protein in rabbit hepatocytes.
Pathobiology
58:89,
1990[Medline]
[Order article via Infotrieve]
52.
Schumann RR:
Mechanisms of transcriptional activation of lipopolysaccharide binding protein (LBP).
Prog Clin Biol Res
392:297,
1995[Medline]
[Order article via Infotrieve]
53.
Wong HR,
Pitt BR,
Su GL,
Rossignol DP,
Steve AR,
Billiar TR,
Wang SC:
Induction of lipopolysaccharide-binding protein gene expression in cultured rat pulmonary artery smooth muscle cells by interleukin 1 beta.
Am J Respir Cell Mol Biol
12:449,
1995[Abstract]
54.
Shalabi EA:
Acetaminophen inhibits the human polymorphonuclear leukocyte function in vitro.
Immunopharmacology
24:37,
1992[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Hirose, S. Murosaki, Y. Yamamoto, Y. Yoshikai, and T. Tsuru
Daily Intake of Heat-Killed Lactobacillus plantarum L-137 Augments Acquired Immunity in Healthy Adults
J. Nutr.,
December 1, 2006;
136(12):
3069 - 3073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Lee, C. W. Frevert, G. Matute-Bello, M. M. Wurfel, V. A. Wong, S.-M. Lin, J. Ruzinski, S. Mongovin, R. B. Goodman, and T. R. Martin
TLR-4 pathway mediates the inflammatory response but not bacterial elimination in E. coli pneumonia
Am J Physiol Lung Cell Mol Physiol,
November 1, 2005;
289(5):
L731 - L738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Strieter, K. M. Starko, R. I. Enelow, I. Noth, V. G. Valentine, and the other members of the Idiopathic Pulmonary Fibr
Effects of Interferon-{gamma} 1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med.,
July 15, 2004;
170(2):
133 - 140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. I. Ojielo, K. Cooke, P. Mancuso, T. J. Standiford, K. M. Olkiewicz, S. Clouthier, L. Corrion, M. N. Ballinger, G. B. Toews, R. Paine III, et al.
Defective Phagocytosis and Clearance of Pseudomonas aeruginosa in the Lung Following Bone Marrow Transplantation
J. Immunol.,
October 15, 2003;
171(8):
4416 - 4424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Nabbe, P. L. van Lent, A. E. Holthuysen, J. K. Kolls, S. Verbeek, and W. B. van den Berg
Fc{gamma}RI Up-Regulation Induced by Local Adenoviral-Mediated Interferon-{gamma} Production Aggravates Chondrocyte Death during Immune Complex-Mediated Arthritis
Am. J. Pathol.,
August 1, 2003;
163(2):
743 - 752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. H. Segal, L. Ding, and S. M. Holland
Phagocyte NADPH Oxidase, but Not Inducible Nitric Oxide Synthase, Is Essential for Early Control of Burkholderia cepacia and Chromobacterium violaceum Infection in Mice
Infect. Immun.,
January 1, 2003;
71(1):
205 - 210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Metelitsa, S. D. Gillies, M. Super, H. Shimada, C. P. Reynolds, and R. C. Seeger
Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on Fcgamma RII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis
Blood,
May 13, 2002;
99(11):
4166 - 4173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Liuzzo, A. N. Vallejo, S. L. Kopecky, R. L. Frye, D. R. Holmes, J. J. Goronzy, and C. M. Weyand
Molecular Fingerprint of Interferon-{{gamma}} Signaling in Unstable Angina
Circulation,
March 20, 2001;
103(11):
1509 - 1514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pricop, P. Redecha, J.-L. Teillaud, J. Frey, W. H. Fridman, C. Sautes-Fridman, and J. E. Salmon
Differential Modulation of Stimulatory and Inhibitory Fc{{gamma}} Receptors on Human Monocytes by Th1 and Th2 Cytokines
J. Immunol.,
January 1, 2001;
166(1):
531 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. H. Segal, N. Sakamoto, M. Patel, K. Maemura, A. S. Klein, S. M. Holland, and G. B. Bulkley
Xanthine Oxidase Contributes to Host Defense against Burkholderia cepacia in the p47phox-/- Mouse Model of Chronic Granulomatous Disease
Infect. Immun.,
April 1, 2000;
68(4):
2374 - 2378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract